Aligos Therapeutics, Inc. Common Stock
ALGS Real Time Price USDRecent trades of ALGS by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by ALGS's directors and management
Government lobbying spending instances
-
$110,000 Jul 20, 2023 Issue: Labor Issues/Antitrust/Workplace
Estimated quarterly lobbying spending
ALGS Revenue by Segment or Geography
New patents grants
-
Patent Title: Anti-viral compounds Mar. 18, 2025
-
Patent Title: Modulators of thr-β and methods of use thereof Dec. 31, 2024
-
Patent Title: Modified short interfering nucleic acid (sina) molecules and uses thereof Oct. 29, 2024
-
Patent Title: Anti-viral compounds Aug. 20, 2024
-
Patent Title: Methods and compositions for targeting pd-l1 Jun. 25, 2024
-
Patent Title: Bicyclic compounds Apr. 16, 2024
-
Patent Title: Bicyclic compounds Apr. 09, 2024
-
Patent Title: Anti-viral compounds Apr. 09, 2024
-
Patent Title: Methods and compositions for targeting pd-l1 Mar. 26, 2024
-
Patent Title: Bicyclic pyridazinones and methods of use thereof Jan. 02, 2024
-
Patent Title: Substituted imidazo[1,5-a]pyrazines for the treatment of hepatitis b Dec. 19, 2023
-
Patent Title: Modulators of thr-β and methods of use thereof Dec. 12, 2023
-
Patent Title: Tricyclic compounds Nov. 21, 2023
-
Patent Title: Oxindoles and methods of use thereof Oct. 24, 2023
-
Patent Title: Modified cyclic dinucleoside compounds as sting modulators Oct. 17, 2023
-
Patent Title: 2-pyridones and methods of use thereof Oct. 17, 2023
-
Patent Title: Pyrrole compounds Oct. 03, 2023
-
Patent Title: Methods and compositions for targeting pd-l1 Sep. 19, 2023
-
Patent Title: Methods and compositions for targeting pd-l1 Sep. 19, 2023
-
Patent Title: Methods of reducing virus molecule levels Mar. 28, 2023
-
Patent Title: Bicyclic and tricyclic compounds Feb. 28, 2023
-
Patent Title: Modified short interfering nucleic acid (sina) molecules and uses thereof Jan. 10, 2023
-
Patent Title: Modified gapmer oligonucleotides and methods of use Oct. 11, 2022
-
Patent Title: Heterocyclic compounds Oct. 11, 2022
-
Patent Title: Compounds targeting prmt5 Dec. 14, 2021
-
Patent Title: Pyrrole compounds Dec. 07, 2021
-
Patent Title: S-antigen transport inhibiting oligonucleotide polymers and methods Nov. 09, 2021
-
Patent Title: Tricyclic compounds Oct. 05, 2021
-
Patent Title: Modulators of thr-β and methods of use thereof Aug. 17, 2021
-
Patent Title: Bicyclic sulfonamides Jun. 15, 2021
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Recent insights relating to ALGS
Recent picks made for ALGS stock on CNBC
ETFs with the largest estimated holdings in ALGS
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $ALGS stock a Buy, Sell, or Hold?
- What is the price target for $ALGS stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $ALGS stock?
- Who owns the most shares of $ALGS stock?
- What funds own $ALGS stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view ALGS Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.